Top

--Briefing to Industry on the Advance Anticonvulsant System (AAS) and the Improved Nerve Agent Treatment Systems Program (INATS)

Active

USA-SNOTE-050203-003Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The Medical Identification and Treatment Systems Product Manager from the Chemical, Biological, and Medical Project Management Office is organizing a briefing for prospective offerors regarding the Advance Anticonvulsant System (AAS) and the Improved Nerve Agent Treatment Systems (INATS) programs. This event will take place on March 8, 2005, from 9 AM to 3 PM at the CBMS Joint PMO in Frederick, Maryland. The session will provide detailed information about the development efforts focused on protecting warfighters from the toxic effects of nerve agent exposure. Specific discussions will cover the administration of Midazolam via a single-chambered autoinjector in the AAS program and the sequential delivery of atropine and an oxime using a two-chambered autoinjector in the INATS program. Participants will gain in-depth insight into the autoinjector components and related development work essential for both programs. A question and answer segment will follow the presentation, providing an opportunity for clarification and discussion. The briefing is open to all interested prospective offerors, who are encouraged to attend by reserving their spot via email with Dr. George Schieferstein. This initiative is managed under the Department of Defense and aims to advance chemical and biological medical countermeasure capabilities, ensuring readiness and protection for military personnel.

General Info

Briefing on AAS and INATS autoinjector programs, March 8, 2005, Frederick, MD, for offerors.

Agency

Department Of Defense → W6QK Acc-Rsa

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedFeb 3

special-notice

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Defense → W6QK Acc-Rsa

ContactsNo contacts available

OfficeREDSTONE ARSENAL, AL, 35898-5000, USA

Organization / AgencyDepartment Of Defense → W6QK Acc-Rsa

Office AddressREDSTONE ARSENAL, AL, 35898-5000, USA

ContactsNo contact information available

Full Description

The Medical Identification and Treatment Systems Product Manager of the Chemical, Biological, and Medical Project Management Office, is hosting a briefing to interested prospective offerors to present current information on the AAS and INATS programs . The briefing will be held on March 8, 2005, 9AM to 3PM at CBMS Joint PMO, 64 Thomas Johnson Drive, Frederick, Maryland. The MITS Pharmaceutical Manager will discuss the advance development of the AAS and INATS necessary to provide warfighters with prote ction against the toxic effects of exposure to nerve. Midazolam will be administered with a single-chambered autoinjector in the AAS program while atropine and an oxime will be sequentially administered by a 2-chambered autoinjector in the INATS program. Participants should expect to obtain specific information on the autoinjector-related work required for both programs. A question and answer session will be held following the briefing. This release of information is open to any interested prospective o fferor and all are encouraged to attend. To reserve a space in this briefing, email your request to participate to Dr. George Schieferstein using the following email address: contact@example.gov.